https://www.selleckchem.com/pr....oducts/ly3295668.htm
Finally, two case studies of ESCC patients were presented to further verify the results observed in the PDX models. Results The pathological characteristics of the serially passaged patient tumor-derived xenografts established in our study were in line with those of the original ESCC patient samples. The group receiving anlotinib and cisplatin plus radiotherapy exhibited the strongest antitumor response among the groups. Moreover, the ideal anticancer effects of anlotinib combined with chemoradiotherapy observed in clinical patients w
Like
Comment
Share
